Exercise or conversion by Gallagher Carol Giltner of 30000 shares of NewAmsterdam Pharma subject to Rule 16b-3
| NAMS Stock | 19.85 0.95 4.57% |
Slightly above 59% of NewAmsterdam Pharma's investor base is looking to short. The analysis of the overall investor sentiment regarding NewAmsterdam Pharma suggests that many traders are alarmed. NewAmsterdam Pharma's investing sentiment can be driven by a variety of factors including economic data, NewAmsterdam Pharma's earnings reports, geopolitical events, and overall market trends.
NewAmsterdam |
Filed transaction by Frazier Lifesciences Acqu director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
NewAmsterdam Pharma's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the NewAmsterdam Pharma's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
NewAmsterdam Pharma Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards NewAmsterdam Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
NewAmsterdam Pharma Fundamental Analysis
We analyze NewAmsterdam Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NewAmsterdam Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NewAmsterdam Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
NewAmsterdam Pharma is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
NewAmsterdam Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NewAmsterdam Pharma stock to make a market-neutral strategy. Peer analysis of NewAmsterdam Pharma could also be used in its relative valuation, which is a method of valuing NewAmsterdam Pharma by comparing valuation metrics with similar companies.
Peers
NewAmsterdam Pharma Related Equities
| CUE | Cue Biopharma | 11.93 | ||||
| MOLN | Molecular Partners | 0.17 | ||||
| ELYM | Eliem Therapeutics | 1.30 | ||||
| INBX | Inhibrx | 2.37 |
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.